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Publication of the “WHO Guidelines on ethical is-
sues in public health surveillance” (henceforth referred 
to as “WHO Guidelines” [1] by the World Health Or-
ganisation (WHO) provides the international commu-
nity with a reference document that identifies a set of 
ethical guidelines for public health surveillance. 
Coincidentally, though not intentionally, the WHO 
Guidelines were published shortly after the publication 
in Italy of the Decree 3rd March, 2017 “Identification 
of systems for the surveillance of registries of mortality, 
tumours and other pathologies” [2], a landmark refer-
ence document to provide Italy with a national health 
information system that is both adequate and durable.
The present Commentary will first look into the two 
documents separately and then compare them.
THE WHO GUIDELINES: A NEW APPROACH?
The immediate reaction to the new WHO Guidelines 
is: how do they compare with others already issued? 
This question is best addressed by dividing it into two 
parts: one concerning biomedical ethics in general, and 
the other concerning public health ethics in particular.
1. In the matter of biomedical ethics in general, some 
of the compilers of the guidelines rightly pointed out 
that, for the public health surveillance sector, the WHO 
Guidelines do not differ substantially from the numer-
ous other ethical frameworks for biomedical ethics 
published since the middle of the last century [3]. The 
succession of frameworks for biomedical ethics and the 
timing of the WHO Guidelines should not, however, be 
taken as representing a new approach to the reference 
values: all the documents are based on a common set of 
basic values. The WHO Guidelines, naturally, identify 
elements that “are of particular importance for public 
health surveillance” and that “represent the backbone 
of the guidelines” (p. 21): common good, equity, re-
spect for persons, good governance, all of which were 
amply acknowledged in earlier documents (e.g. “The 
Barcelona Declaration on Basic Ethical Principles in 
Bioethics and Biolaw” [4], which should “be conceived 
as a conceptual clarification and articulation of major 
ethical principles, which are central to international 
concerns for a universal bioethics and biolaw” [5]).
2. In the matter of public health ethics in particular, as 
noted by The Lancet, the WHO Guidelines are the 
“first document to address the challenge of surveillance 
on a global stage and the first set of international guide-
lines in which the ethics of public health (…) serves as 
a normative framework”. Thanks to the efforts of vari-
ous national or local institutions, as well as to experts in 
the field, numerous frameworks for the ethics of pub-
lic health surveillance [6, 7] were in fact already avail-
able. Indeed, the WHO Guidelines “are rooted in the 
tradition of public health ethics” [8]; nor do they stray 
from a body of principles of public health ethics and, in 
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are today consolidated and widely shared. The novelty 
is thus not in the contents but rather in the interna-
tional reach of the document, in its completeness and 
in its organic structure, given that it addresses all the 
key ethical considerations applicable to public health 
surveillance in a single document.
THE ITALIAN DECREE ON SURVEILLANCE 
AND REGISTRIES
The Decree of 3rd March, 2017 follows on from ar-
ticle 12 of Decree law no. 179 of 18th October, 2012 
[9], which was converted into Law no. 221 of 17th De-
cember, 2012 [10]. The intervening stages necessary for 
the Decree’s enforcement were: the “Opinion on a draft 
Decree of the President of the Council of Ministers on 
surveillance systems and registries (23rd July, 2015) by 
the Data Protection Authority [11] and the agreement 
with the Permanent Conference for Relations between 
the State, the Regions and the Autonomous Provinces 
of Trento and Bolzano on 24th November, 2016 [12].
The Decree identifies 31 surveillance systems and 
15 registries of nationally significant diseases, the pur-
pose of which is to ensure prevention, diagnosis, care 
and rehabilitation, health planning, healthcare quality 
checks, and assessment of healthcare assistance and of 
scientific research in the medical, biomedical and epi-
demiological fields.
For each of the 31 surveillance systems and each 
registry the Decree names the reference institution: in 
many cases this is the Istituto Superiore di Sanità (ISS, 
Italian National Institute of Health), while in others it 
is the Ministry of Health.
The Decree divides the surveillance systems and reg-
istries into three groups:
• surveillance systems and registries of national or re-
gional importance (attachment A);
• surveillance systems and registries of national impor-
tance formerly governed by national regulations (at-
tachment B);
• surveillance systems and registries of purely regional 
importance (attachment C).
These systems and registries are essential for ensur-
ing prevention, diagnosis, treatment and rehabilitation, 
healthcare planning, treatment quality checks, and as-
sessment of healthcare assistance and of scientific re-
search in the medical, biomedical and epidemiological 
fields [13].
THE WHO GUIDELINES AND THE ITALIAN 
DECREE: WELL ATTUNED (BUT AWAITING 
COMPLETION)
The Italian Decree 3rd March, 2017 is in tune with 
the recommendations of the WHO Guidelines from 
the very beginning (the heading of the WHO guide-
line no. 1 is “Countries have an obligation to develop 
appropriate, feasible, sustainable public health sur-
veillance systems. Surveillance systems should have a 
clear purpose and a plan for data collection, analysis, 
use and dissemination based on relevant public health 
priorities”). The text of the first guideline goes on to 
state that: “The duty to protect population health is 
the foundation of an affirmative responsibility to con-
duct public health surveillance. The exercise of that 
responsibility may be assigned to subnational gov-
ernmental bodies. Without public health surveillance 
systems, population health cannot be protected and 
inequalities cannot be adequately addressed. Inatten-
tion to pressing public health needs leads to erosion of 
trust (…). The importance of population health thus 
imposes upon States an obligation to develop systems 
that capture data critical to identifying and respond-
ing to (outbreaks of) infectious diseases, epidemic 
threats and the toll exacted by injuries and chronic dis-
ease, which demand environmental and occupational 
monitoring or investigation”. The Italian Decree of 3rd 
March, 2017 names the ISS as the appropriate institu-
tion for the management of surveillance systems and 
registries, acknowledging that its mission is the promo-
tion and protection of public health both in Italy and 
at international level, through “research, surveillance, 
regulation, control, prevention, communication, con-
sultation and training” [14, 15].
Surveillance systems and registries are not an end in 
themselves: as the first of the WHO Guidelines recog-
nises, “once surveillance data are available, Member 
States have the moral duty to use the data actively to 
promote better health outcomes”. This task is also fully 
part of the mission of the ISS.
Although the WHO Guidelines and the Italian De-
cree are substantially in agreement, the latter does not 
give full effect to the former’s guideline no. 2, which 
states that “Countries have an obligation to develop 
appropriate, effective mechanisms to ensure ethical 
surveillance (…). Countries should have appropriate, 
effective mechanisms for ensuring adherence to ethi-
cal standards in both emergency and non-emergency 
situations”. We might ask what form such mechanisms 
should take, given that the Decree makes no mention 
of them. The WHO document includes examples of 
“mechanisms for ensuring adherence to ethical stan-
dards” that have been adopted in some institutions 
or nations. Ethics committees would appear to be the 
most appropriate institutions to pronounce on the ethi-
cal soundness of public surveillance initiatives.  How-
ever, we should ask whether, at least in Europe, ethics 
committees are in a position to perform this task. The 
responsibilities already assigned to these committees 
for clinical trials, particularly in view of the full imple-
mentation of Regulation (EU) 536/20014 [16], place 
an inescapable burden of work concerning clinical trials 
alone, which risks detracting attention from anything 
else, particularly anything concerning the ethics of clini-
cal practice or public health. It is to be hoped that in 
Italy this issue will be properly addressed when the or-
ganisation of ethics committees is reviewed, as envis-
aged in the law of 22nd December, 2017 [17], and that 
the institution of ethics committees for clinical practice, 
public health and research separate from those for clini-
cal trials will be promoted and put to good use. There 
are in Italy committees with many years of experience 
in these fields, including the Ethics Committee of the 
ISS, whose experience of evaluation goes well beyond 
clinical trials and which from its inception has been 
extensively concerned with the ethics of public health 











and public health surveillance. This is well illustrated 
in the “Codice di Etica dell’Istituto Superiore di San-
ità” (Code of Ethics of the Italian Institute of Health) 
[18], the fourth chapter of which addresses the issues of 
public health research and interventions. This chapter 
indicates certain requisites (notably: efficacy, propor-
tionality, necessity, information, consent, protection of 
personal data, transparency) that are totally in line with 
the WHO Guidelines.
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